Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference33 articles.
1. Imatinib mesylate—a new oral targeted therapy;Wood;N Engl J Med,2002
2. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population;Bower;J Clin Oncol,2016
3. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib;Gambacorti-Passerini;J Natl Cancer Inst,2011
4. International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009
5. Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study;Cortes;Clin Lymphoma Myeloma Leuk,2016
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib;Annals of Hematology;2023-11-28
2. High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors;Leukemia & Lymphoma;2023-08-09
3. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity;ESC Heart Failure;2022-03-31
4. Management of Acute Coronary Syndrome in Cancer Patients: It’s High Time We Dealt with It;Journal of Clinical Medicine;2022-03-24
5. Nilotinib related acute myocardial infarction with nonobstructive coronary arteries: a case report and literature review;BMC Cardiovascular Disorders;2022-02-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3